Taken together, these studies provide strong evidence of the therapeutic effects of ETI for PwCF who have at least one copy of F508del-CFTR and advanced lung disease, indicating that this CF population can benefit clinically from this therapy. Here, CFTR is linked to cystic fibrosis.